ARTICLE | Clinical News
KPT-9274: Phase I started
July 11, 2016 7:00 AM UTC
Karyopharm began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral KPT-9274 with or without extended-release niacin given 3 times a week every other day of a 28-day c...